A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in ...

Toronto, Ontario—A novel imaging approach— 68 Ga-DOTATATE PET/CT—can more accurately differentiate residual/recurrent tumors from post-surgery scar tissue in patients with head and neck paragangliomas ...

June 21, 2012 (Miami Beach, Florida) — Molecular imaging with a method that detects hormonally active tissues in the body can improve the care of patients with neuroendocrine cancer, researchers said ...

Comparison of concurrent chemoradiation with stereotactic body radiation therapy versus conventionally fractionated radiation therapy following induction chemotherapy for unresected locally advanced ...

SAINT-GENIS-POUILLY, France, March 4, 2014 /CNW/ - Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have ...

DENVER--(BUSINESS WIRE)--Rocky Mountain Cancer Centers (RMCC), a practice in The US Oncology Network, is the first in the Rocky Mountain region, and one of only a handful of sites in the United States ...

QEII Foundation donors are bringing Atlantic Canada’s first gallium-68 DOTATATE tracer to the QEII to help diagnose and treat patients with neuroendocrine cancer Sharon Needham never expected to see ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA approved Netspot, the first kit ...

Access to advanced diagnostic imaging has taken a significant leap forward with the introduction of Gallium-68 Dotatate PET-CT scans now available through Mobile Imaging's mobile service. Starting ...

The QUANTM Irradiation System can generate 68 Ga at record breaking levels. (Courtesy: ARTMS Products) Gallium-68 (68 Ga) is a positron emitter that’s becoming established as a valuable diagnostic ...

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their ...